The New England Journal of Medicine (NEJM). Un ensayo internacional extiende la eficacia de la inmunoterapia a más pacientes de cáncer de pulmón

- Combinar inmunoterapia con quimioterapia en pacientes de carcinoma epidermoide con metástastais “aumenta de manera significativa” la supervivencia de los pacientes, escriben los autores en The New England Journal of Medicine
- El carcinoma epidermoide representa entre el 20% y el 30% de todos los casos de cáncer de pulmón y tiene peor pronóstico que otras variantes. Es uno de los cánceres en que menos han avanzado los tratamientos
- Los pacientes que recibieron quimioterapia e inmunoterapia ampliaron su supervivencia en casi 16 meses de media, frente a los 11,3 meses de quienes recibieron solo quimioterapia
An international clinical trial led by the oncologist Luis Paz-Ares, member of the iLUNG team, has substantially increased the group of lung cancer patients who may benefit from immunotherapy.
The clinical trial focuses on squamous cell carcinoma, in advanced stages of the disease presenting metastasis. The results have been published in the prestigious New England Journal of Medicine (NEJM) and show that immunotherapy, when administered alongside conventional chemotherapy, “significantly increases” patient survival. For Paz-Ares, this result “offers new possibilities against a subtype of lung cancer in which, over the past two decades, the possibilities of treatment have barely advanced”.
- Combining immunotherapy with chemotherapy in patients with metastatic squamous cell carcinoma “significantly increases” the survival of patients, write the authors in The New England Journal of Medicine
- Squamous cell carcinoma represents between 20% and 30% of all cases of lung cancer and has a worse prognosis than other variants. It is a form of cancer for which the least amount of progress has been made in terms of treatment
- Patients who received chemotherapy and immunotherapy extended their survival by almost 16 months on average, compared to 11.3 months for those who received chemotherapy alone.
Artículo de referencia: Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. L. Paz-Ares et al. The New England Journal of Medicine (2018). DOI: 10.1056/NEJMoa1810865
Original publication: Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. L. Paz-Ares et al. The New England Journal of Medicine (2018). DOI: 10.1056/NEJMoa1810865